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Prophylaxis of pyelonephritis by aminoglycosides accumulated in the kidney
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Universitaire Vaudois, Lausanne, Switzerland
When given prophylactically, gentamicin accumulates and persists in the rat
kidney and affords protection against obstructive acute Escherichia coli
pyelonephritis. Similar protection is observed after administration of amikacin,
netilmicin and tobramycin, which accumulate to various degrees in the renal
parenchyma. In those animals developing pyelonephritis despite aminoglycoside
prophylaxis, renal infection and inflammation are reduced during the acute phase
of the disease. This results in almost complete protection against renal scarring
later on.
Administree a titre prophylactique, la Gentamicine s'accumule dans le rein du rat
et le protege contre l'apparition de pyelonephrite aigue a E. coli. Un effet
protecteur identique est observe apres administration d'Amikacine, de Netil-
micine, et de Tobramycine, qui s'accumulent a des degres divers dans le
parenchyme renal.
Chez l'animal, lorsqu'apparait une py61on6phrite, malgre le traitement prophy-
lactique par les aminoglycosides, l'infection et rinflammation resales sont
diminuees durant la phase aigue de la maladie. Ceci reduit le risque de lesion et de
formation ulterieure de tissu cicatriciel.
Introduction
The accumulation and persistence of aminoglycoside antibiotics in the renal
parenchyma has been reported in man and in animals. Although often considered to
be responsible for the nephrotoxicity of these antibiotics, these pharmacokinetic
properties have rarely been used to a therapeutic advantage.
In a rat model of ascending pyelonephritis (Brooks, Lyons & Braude, 1974), we
determined if persistence of gentamicin in the kidney can prevent the occurrence of
pyelonephritis and we compared the prophylactic activity of different amino-
glycosides against the development of pyelonephritis.
Material and Methods
Production of pyelonephritis
Pyelonephritis was produced by injecting into the bladder a 1-ml inoculum of broth
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containing 103 of Escherichia coli. Reflux into both ureters occurred consistently
when urine appeared at the external urethral meatus. A silk ligature was then
loosely tied around the left ureter, creating partial obstruction. The ligature was left
in place for 18 h, and then carefully removed from the outside. During the
obstructive phase, infection developed above the ligature and spread to the left
kidney, provoking an acute suppurative pyelonephritis.
Three days after infection, the kidney was enlarged and had numerous small
abscesses on its surface, spreading into the papilla. The most reliable measure of the
degree of inflammation in the left kidney was its weight. During the acute phase, it
increased in proportion to the inflammation, whereas its decline in the chronic
phase reflected the amount of kidney destruction. In order to minimize the variation
of kidney weights between animals, the ratio of the weight of the left pyelonephritic
kidney to that of the right non-pyelonephritic kidney weight was used (Glauser,
Lyons & Braude, 1978). This ratio is 1 in normal rats. The grade of infection was
expressed by the logarithm of the number of cfu per gram of kidney.
Prophylaxis of acute pyelonephritis with gentamicin
The first series of experiments was designed to test whether gentamicin would
prevent pyelonephritis if given before operation.
Four groups of rats received gentamicin intra-muscularly as follows:
the first group received 1 injection of 4 mg/kg of gentamicin 72 h before
operation;
the second group received 3 injections of gentamicin at 12 h intervals, the last
injection 72 h before operation;
the third group received 7 injections of gentamicin at 12 h intervals, the last
injection 18 h before operation.
The control group received saline only.
Prophylaxis of acute and chronic pyelonephritis with amikacinr gentamicin,
netilmicin or tobramycin
Groups of animals received 3 intramuscular doses of aminoglycoside at 12-h
intervals, the last dose 72 h before operation. Control rats received 3 injections of
saline. The animals were killed 3 days after operation in the acute pyelonephritis
experiments, or 3 months later in the chronic pyelonephritis experiments. The doses
of gentamicin and tobramycin were 4 mg/kg, of 20 mg/kg for amikacin and of
5 mg/kg for netilmicin.
The strain of E. coli used for infecting the rats was inhibited by 2 fxg of genta-
micin/ml, 2 fig of tobramycin/ml, 4 fig of amikacin/ml and 1 /zg of netilmicin/ml.
The levels of aminoglycosides were measured in the kidney homogenates by the agar
diffusion method diluting known amounts of the aminoglycosides in normal kidney
homogenate as standards.
Kidney tissue levels of prophylactic aminoglycosides
In order to determine the amount of antibiotics that had accumulated and persisted
in the kidney parenchyma, different groups of rats were killed 3 days after
completion of the aminoglycoside prophylaxis, at the time experimental rats were
operated on and infected.
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Results
Prophylaxis of acute pyelonephritis with gentamicin
Thirteen out of the 17 control rats receiving prophylactic saline (76%) suffered
severe unilateral acute pyelonephritis. The same incidence (22/28, 79%) was seen
after 1 single injection; but only 20% (4/20) of the rats challenged 72 h after the last
of 3 injections showed evidence of pyelonephritis. In the last group, among 8 rats
infected 12 h after the last of 7 injections, none of the kidneys showed pyelonephritis.
The question then arose as to whether the low incidence of pyelonephritis seen
72 h after 3 injections was due to urine levels of gentamicin sufficient to kill the
infecting inoculum during the partial obstruction. In this group of rats receiving 3
injections, the pelvic fluid was cloudy at the time of removal of the partial
obstruction, and contained a mean of 107 viable E. coli/ml. In addition no
measurable antibiotic activity was detected by bioassay at this time in the urines.
Thus in these experiments gentamicin accumulation retained very effective
antimicrobial activity in the rat kidney parenchyma and prevented pyelonephritis
when given before infection. It is widely accepted that in patients, antimicrobial
drugs must reach adequate urinary concentrations in order to sterilize the urinary
infection that might be responsible for kidney involvement. These results in the rat
suggest that accumulation and persistence of gentamicin in the kidney parenchyma
can prevent its infection in the absence of antibacterial activity in the urine.
Prophylaxis of acute and chronic pyelonephritis with amikacin, gentamicin,
netilmicin or tobramycin
In comparison with gentamicin, the newer aminoglycoside antibiotics accumulate
to a lesser extent in the renal tissue and might display a different degree of protection
in this animal model of pyelonephritis.
The second series of experiments compared the effect of four aminoglycosides
given prophylactically on the incidence and on the severity of acute and chronic
pyelonephritis.
The incidence of pyelonephritis (acute and chronic) was reduced from 61%
(78/128) in control rats to 33% (20/60, P < 0001) in rats receiving intramuscular
prophylactic amikacin, to 25% (16/65, P < 0001) after intramuscular gentamicin,
to 36% (19/53, P < 0001) after intramuscular netilmicin, and to 29% (15/51,
P < 0001) after intramuscular tobramycin.
Again this protection was conferred even though at the time of operation no
residual antimicrobial activity in the serum was detected by bioassay, and only
traces of antibiotics were present in the urine, well below the MICs for the 4 amino-
glycoside antibiotics for the infecting E. coli. Protection was therefore due to the
antimicrobial activity of the accumulated and persistent aminoglycosides in the
kidney parenchyma.
This protection was not complete and between a quarter and a third of the animals
given prophylactic aminoglycosides developed pyelonephritis.
Table I analyses the severity of inflammation during acute pyelonephritis and of
subsequent parenchymal destruction during chronic pyelonephritis, as expressed by
the ratio of the left kidney weight to the right kidney weight. As can be seen, there
was a marked reduction of inflammation in the four groups of rats developing
pyelonephritis despite aminoglycoside prophylaxis. This reduction of inflammation
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Table I. Severity of acute and chronic pyelonephritis as expressed by the
kidney weight ratio after prophylactic aminoglycoside antibiotics
Group of rats
Controls
Amikacin
Gentamicin
Netilmicin
Tobramycin
Kidney weight
acute pyelonephritis
1-97 ±0-3
1-60 ±0-3*
1-57 ± 0-2*
1-57 ±0-2*
1-40 ±0-2*
ratio (left to right)
chronic pyelonephritis
0-56 ± 0 3
0-89 ±0-1*
0-96 ± 0-1*
088 ± 0 1 *
0-93 ±0-1*
*/><0001 when compared to controls.
Table II. Severity of infection during acute and chronic pyelonephritis after
prophylactic aminoglycoside antibiotics
- Log|0cfu/g of kidney
uroupo rats acute pyelonephritis chronic pyelonephritis
Controls
Amikacin
Gentamicin
Netilmicin
Tobramycin
8-12
6-82
687
638
695
±
±
±
±
±
07
11*
0 3 *
06*
0 3 *
438
464
4-91
4-98
456
±
±
±
±
±
10
05
1-1
0 3
11
*/»< 0-001 when compared to controls.
during the acute phase of the disease was followed by a striking reduction in the
extent of parenchymal destruction 3 months later compared with the destruction
observed in controls.
Table II analyses the severity of infection during acute and chronic pyelonephritis
as expressed by the number of CFU of E. coli recovered from kidney homogenates.
During the acute phase of pyelonephritis, there was a significant reduction of
infection in the four groups of rats receiving prophylactic antibiotics. However this
reduction was not found 3 months after prophylaxis.
Kidney tissue levels of prophylactic aminoglycosides
The renal tissue level of gentamicin (71 ± 19 /ig/g of kidney tissue) was significantly
higher than the level of amikacin (44 ± 13 ^g/g) of netilmicin (43 ± 22 /ig/g) and of
tobramycin (24 ± 15/ig/g). Amikacin, which was given in a dosage five times
greater than gentamicin and tobramycin, did not show a corresponding increase in
the degree of accumulation. Its relative accumulation was therefore the least of all
four aminoglycosides studied.
Discussion
Rats given 7 prophylactic doses of gentamicin, the last dose only 12 h before
induction of pyelonephritis, displayed complete protection against kidney infection
and suppuration. This protection was probably due to there being sufficient anti-
biotic in the urine to kill the infecting inoculum. In contrast, protection was still
important, but not complete when aminoglycosides were reduced to 3 doses, the last
dose given 72 h before the induction of pyelonephritis. This protection was
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conferred in the absence of detectable active antibiotic in the urine, and could there-
fore be attributed to antibiotic stored in the renal parenchyma. Protection against
pyelonephritis was observed despite the presence of 107 bacteria/ml in pelvic urine
and in the presence of obstruction. It has been shown (Stamey, Govan & Palmer,
1965) that to sterilize the urine of infected patients with kidney involvement, it is
sufficient that antimicrobial drugs reach adequate urinary concentrations. The
experiments presented here show that aminoglycosides persisting in the kidney
prevent obstructive pyelonephritis even if there is not enough antimicrobial activity
in the urine to abolish heavy pelvic infection.
In the experiments that compared the prophylactic activity of 3 doses of four
aminoglycosides, one could have expected complete protection, if one correlate the
levels of each aminoglycoside achieved in the kidney parenchyma at the time of
operation and the MICs of the test organism. These levels, however, were
measured in whole kidney homogenates and it is well established that aminoglyco-
sides accumulate to a lesser extent in the medulla and papilla of the kidney where
ascending pyelonephritis develops, than in the cortex (Luft et al., 1978). Further-
more, accumulated aminoglycosides are mostly located inside the tubular cells,
bound to cell organelles, whereas infection starts in the interstitium. Lastly the high
concentrations of urea and other solutes in the papilla and medulla decrease the
antibacterial activity of aminoglycosides in the kidney. For these reasons at least, the
levels of aminoglycosides as measured in these experiments did not correlate with
complete in-vivo protection against the development of pyelonephritis. The anti-
bacterial activity of the accumulated aminoglycosides in the kidney parenchyma was
not sufficient to suppress acute pyelonephritis completely, as was achieved when the
antibiotics were given 12 h before infection.
Those animals that did develop pyelonephritis despite aminoglycoside prophy-
laxis had less severe acute kidney infection and inflammation. This resulted 3
months later in almost complete protection against renal scarring.
Previous experiments have suggested that the formation of kidney scars results less
from persisting infection than from suppurative necrosis during the acute phase of
pyelonephritis (Glauser et al., 1978). In the present experiments, next to diminished
infection, aminoglycoside prophylaxis afforded significant reduction of inflam-
mation in those treated animals that developed acute pyelonephritis reflected 3
months later by a striking reduction of kidney destruction. This observation under-
lines the critical role of acute inflammation in the development of parenchymal
damage.
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